Gottlieb Broaches Real-World Impact Of White House’s List Price Ad Disclosure Idea

May 15, 2018
Facing a White House mandate to study whether FDA can require disclosure of drug list prices in direct-to-consumer ads, FDA Commissioner Scott Gottlieb insinuated it was an open question whether list prices are the best way to inform consumers of a drug’s potential out-of-pocket cost. However, an agency spokesperson declined to say whether FDA will consider mandating disclosure of a different measure instead of list price. The White House blueprint for lowering drug prices, released Friday (May 11), includes one...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.